Literature DB >> 9927682

Ectopic expression of E47 or E12 promotes the death of E2A-deficient lymphomas.

I Engel1, C Murre.   

Abstract

Mice with null mutations in the E2A gene are highly susceptible to the spontaneous development of thymic lymphomas. To understand better how E2A deficiency may contribute to lymphomagenesis, we have observed the consequences of enforced expression of the E2A gene products E12 and E47 in cell lines derived from lymphomas that arose spontaneously in E2A-deficient mice. E2A-expressing cells are steadily eliminated from lymphoma cultures into which E47 or E12 was introduced. The mechanism underlying the loss of E2A-expressing cells does not involve an arrest in cell-cycle progression. Rather, the E2A proteins activate a programmed cell death pathway in these lymphomas. This E2A-mediated cell death appears to be preceded by a loss of mitochondrial transmembrane potential. These data provide direct evidence that E2A gene products can act as tumor suppressors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927682      PMCID: PMC15339          DOI: 10.1073/pnas.96.3.996

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Mutations that disrupt DNA binding and dimer formation in the E47 helix-loop-helix protein map to distinct domains.

Authors:  A Voronova; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

2.  Inefficient homooligomerization contributes to the dependence of myogenin on E2A products for efficient DNA binding.

Authors:  T Chakraborty; T J Brennan; L Li; D Edmondson; E N Olson
Journal:  Mol Cell Biol       Date:  1991-07       Impact factor: 4.272

3.  B-cell- and myocyte-specific E2-box-binding factors contain E12/E47-like subunits.

Authors:  C Murre; A Voronova; D Baltimore
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

Review 4.  Cell membrane potential analysis.

Authors:  H M Shapiro
Journal:  Methods Cell Biol       Date:  1994       Impact factor: 1.441

5.  The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation.

Authors:  R L Davis; P F Cheng; A B Lassar; H Weintraub
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

6.  MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer.

Authors:  A B Lassar; J N Buskin; D Lockshon; R L Davis; S Apone; S D Hauschka; H Weintraub
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

7.  Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence.

Authors:  C Murre; P S McCaw; H Vaessin; M Caudy; L Y Jan; Y N Jan; C V Cabrera; J N Buskin; S D Hauschka; A B Lassar
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

8.  A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins.

Authors:  C Murre; P S McCaw; D Baltimore
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

9.  Membrane potential can be determined in individual cells from the nernstian distribution of cationic dyes.

Authors:  B Ehrenberg; V Montana; M D Wei; J P Wuskell; L M Loew
Journal:  Biophys J       Date:  1988-05       Impact factor: 4.033

10.  Role of phosphoinositide-derived second messengers in mediating anti-IgM-induced growth arrest of WEHI-231 B lymphoma cells.

Authors:  D M Page; A L DeFranco
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

View more
  36 in total

Review 1.  Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms.

Authors:  M E Massari; C Murre
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities.

Authors:  Lei Nie; Min Xu; Antoaneta Vladimirova; Xiao-Hong Sun
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

3.  Differential gene expression in human hepatocellular carcinoma Hep3B cells induced by apoptosis-related gene BNIPL-2.

Authors:  Li Xie; Wen-Xin Qin; Xiang-Huo He; Hui-Qun Shu; Gen-Fu Yao; Da-Fang Wan; Jian-Ren Gu
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

4.  Identification of cyclin D3 as a direct target of E2A using DamID.

Authors:  Siyuan Song; Jonathan Cooperman; Danielle L Letting; Gerd A Blobel; John Kim Choi
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 5.  Transcriptional regulation of NKT cell development and homeostasis.

Authors:  Louise M D'Cruz; Cliff Y Yang; Ananda W Goldrath
Journal:  Curr Opin Immunol       Date:  2010-02-17       Impact factor: 7.486

6.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

7.  Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Authors:  Ditte Ejegod; Karina Dalsgaard Sørensen; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

8.  The transcription factor Th-POK negatively regulates Th17 differentiation in Vα14i NKT cells.

Authors:  Isaac Engel; Meng Zhao; Dietmar Kappes; Ichiro Taniuchi; Mitchell Kronenberg
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

9.  E2A proteins enforce a proliferation checkpoint in developing thymocytes.

Authors:  Isaac Engel; Cornelis Murre
Journal:  EMBO J       Date:  2003-12-11       Impact factor: 11.598

10.  Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.

Authors:  Charnise Goodings; Rati Tripathi; Susan M Cleveland; Natalina Elliott; Yan Guo; Yu Shyr; Utpal P Davé
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.